These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26215602)
1. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. Shiota M; Yokomizo A Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602 [No Abstract] [Full Text] [Related]
2. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533 [No Abstract] [Full Text] [Related]
3. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141 [TBL] [Abstract][Full Text] [Related]
5. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015. van Soest RJ; de Wit R; van Weerden WM Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524 [No Abstract] [Full Text] [Related]
6. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53. Lu K Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711 [No Abstract] [Full Text] [Related]
7. Is in vitro-acquired resistance to enzalutamide a useful model? Buonerba C; Di Lorenzo G Future Oncol; 2014 Dec; 10(16):2551-3. PubMed ID: 25531044 [No Abstract] [Full Text] [Related]
8. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363 [TBL] [Abstract][Full Text] [Related]
9. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53. Caffo O; Maines F; Veccia A Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376 [No Abstract] [Full Text] [Related]
10. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Martin SK; Kyprianou N Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899 [TBL] [Abstract][Full Text] [Related]
11. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy. Tombal B Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474 [No Abstract] [Full Text] [Related]
12. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer. Thomson D; Charnley N; Parikh O Eur J Cancer; 2014 Mar; 50(5):1040-1. PubMed ID: 24462374 [No Abstract] [Full Text] [Related]
13. Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel. Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M Anticancer Res; 2020 Jan; 40(1):335-339. PubMed ID: 31892584 [TBL] [Abstract][Full Text] [Related]
14. Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or fiction? Schrader AJ; Schrader MG; Cronauer MV Eur Urol; 2014 Feb; 65(2):e22-3. PubMed ID: 24210913 [No Abstract] [Full Text] [Related]
15. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. Lorente D; Bianchini D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; De Bono JS Eur J Cancer; 2014 Mar; 50(5):1042-3. PubMed ID: 24433842 [No Abstract] [Full Text] [Related]
16. Prostate cancer: Niclosamide jumps the hurdle of enzalutamide resistance. Fenner A Nat Rev Urol; 2014 Aug; 11(8):424. PubMed ID: 24980198 [No Abstract] [Full Text] [Related]
17. New treatment options in castration-resistant prostate cancer. Armstrong AJ J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):690-3. PubMed ID: 25995432 [TBL] [Abstract][Full Text] [Related]
18. Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins. Hotte SJ Future Oncol; 2017 Feb; 13(4):369-379. PubMed ID: 27712093 [TBL] [Abstract][Full Text] [Related]
19. [Role of chemotherapy in the treatment of castration resistant prostate cancer]. Uemura H Nihon Rinsho; 2016 Jan; 74(1):143-8. PubMed ID: 26793895 [TBL] [Abstract][Full Text] [Related]
20. Impact of taxanes on androgen receptor signaling. Bai S; Zhang BY; Dong Y Asian J Androl; 2019; 21(3):249-252. PubMed ID: 29900882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]